These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31861319)

  • 21. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.
    Carlo-Stella C; Di Nicola M; Milani R; Guidetti A; Magni M; Milanesi M; Longoni P; Matteucci P; Formelli F; Ravagnani F; Corradini P; Gianni AM
    Blood; 2004 May; 103(9):3287-95. PubMed ID: 14726397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeated hematopoietic stem and progenitor cell mobilization without depletion of the bone marrow stem and progenitor cell pool in mice after repeated administration of recombinant murine G-CSF.
    de Kruijf EJ; van Pel M; Hagoort H; Kruysdijk D; Molineux G; Willemze R; Fibbe WE
    Hum Immunol; 2007 May; 68(5):368-74. PubMed ID: 17462504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Factors affecting mobilization of peripheral blood stem/progenitor cells and apheresis efficiency from healthy donors by rhG-CSF].
    Liang ZY; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):847-51. PubMed ID: 18718074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mobilization as a preparative regimen for hematopoietic stem cell transplantation.
    Chen J; Larochelle A; Fricker S; Bridger G; Dunbar CE; Abkowitz JL
    Blood; 2006 May; 107(9):3764-71. PubMed ID: 16439683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.
    Abraham M; Biyder K; Begin M; Wald H; Weiss ID; Galun E; Nagler A; Peled A
    Stem Cells; 2007 Sep; 25(9):2158-66. PubMed ID: 17525235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in mobilization for the optimization of autologous stem cell transplantation.
    Vose JM; Ho AD; Coiffier B; Corradini P; Khouri I; Sureda A; Van Besien K; Dipersio J
    Leuk Lymphoma; 2009 Sep; 50(9):1412-21. PubMed ID: 19603345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the Complement Cascade Activation During Mobilization of Hematopoietic Stem/Progenitor Cells.
    Grabowska AI; Hawryluk JM
    Methods Mol Biol; 2019; 2017():165-175. PubMed ID: 31197776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
    Uy GL; Rettig MP; Cashen AF
    Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
    Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
    Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
    Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
    Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viagra Enables Efficient, Single-Day Hematopoietic Stem Cell Mobilization.
    Smith-Berdan S; Bercasio A; Rajendiran S; Forsberg EC
    Stem Cell Reports; 2019 Nov; 13(5):787-792. PubMed ID: 31607567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Acting IL-33 Mobilizes High-Quality Hematopoietic Stem and Progenitor Cells More Efficiently Than Granulocyte Colony-Stimulating Factor or AMD3100.
    Alt C; Yuan S; Wu F; Stankovich B; Calaoagan J; Schopies S; Wu JY; Shen J; Schneider D; Zhu Y; Zhao XY; Lippow SM; Bauzon M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1475-1485. PubMed ID: 31163266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100.
    Bonig H; Chudziak D; Priestley G; Papayannopoulou T
    Exp Hematol; 2009 Mar; 37(3):402-15.e1. PubMed ID: 19157683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
    Flomenberg N; Devine SM; Dipersio JF; Liesveld JL; McCarty JM; Rowley SD; Vesole DH; Badel K; Calandra G
    Blood; 2005 Sep; 106(5):1867-74. PubMed ID: 15890685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.